Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Breast Cancer (Tokyo, Japan)|March 29, 2008
Is triple negative a prognostic factor in breast cancer?Reiki Nishimura, Nobuyuki Arima
Breast Cancer (Tokyo, Japan)|January 29, 2008
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survivalReiki Nishimura, Yasuhiro Okumura, Nobuyuki Arima
Molecular and Clinical Oncology|January 26, 2016
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in JapanTomofumi Osako, Reiki Nishimura, Yasuyuki Nishiyama, et al.
Breast Cancer (Tokyo, Japan)|June 7, 2006
Investigation of factors related to periods to ipsilateral breast tumor recurrence after breast-conserving surgery and measures for preventing recurrence in early breast cancerReiki Nishimura, Miwa Akizuki, Rumiko Tashima, et al.
Breast Cancer (Tokyo, Japan)|September 5, 2009
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosisReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
International Journal of Clinical Oncology|December 21, 2006
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort studyKazuharu Kai, Reiki Nishimura, Nobuyuki Arima, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancerTomofumi Osako, Reiki Nishimura, Yasuhiro Okumura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 11, 2003
[A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab]Reiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
World Journal of Surgical Oncology|October 19, 2011
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosisReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
Breast Cancer (Tokyo, Japan)|May 28, 2008
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort studyKazuharu Kai, Nobuyuki Arima, Haruhiko Miyayama, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Breast Cancer (Tokyo, Japan)|March 29, 2008
Is triple negative a prognostic factor in breast cancer?Reiki Nishimura, Nobuyuki Arima
Breast Cancer (Tokyo, Japan)|January 29, 2008
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survivalReiki Nishimura, Yasuhiro Okumura, Nobuyuki Arima
Molecular and Clinical Oncology|January 26, 2016
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in JapanTomofumi Osako, Reiki Nishimura, Yasuyuki Nishiyama, et al.
Breast Cancer (Tokyo, Japan)|June 7, 2006
Investigation of factors related to periods to ipsilateral breast tumor recurrence after breast-conserving surgery and measures for preventing recurrence in early breast cancerReiki Nishimura, Miwa Akizuki, Rumiko Tashima, et al.
Breast Cancer (Tokyo, Japan)|September 5, 2009
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosisReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
International Journal of Clinical Oncology|December 21, 2006
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort studyKazuharu Kai, Reiki Nishimura, Nobuyuki Arima, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancerTomofumi Osako, Reiki Nishimura, Yasuhiro Okumura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 11, 2003
[A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab]Reiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, et al.
World Journal of Surgical Oncology|October 19, 2011
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosisReiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, et al.
Breast Cancer (Tokyo, Japan)|May 28, 2008
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort studyKazuharu Kai, Nobuyuki Arima, Haruhiko Miyayama, et al.
Pageof 8